Leukemia

This early-stage trial is testing an experimental cell therapy called HY035 in people with CD7-positive blood cancers that have returned or not responded to standard treatment. The goal is to see if the therapy is safe and can help achieve remission. Participants receive a single…

This trial tests whether adding rituximab to the standard drug cladribine can eliminate leftover cancer cells in people with hairy cell leukemia, a rare blood cancer. Half the participants receive both drugs at the start, while the other half get rituximab later only if needed. T…

This trial tests a personalized therapy where a patient's own T cells are collected, genetically modified to recognize and attack CD19-positive leukemia cells, and then infused back into the patient. It is designed for children and young adults with relapsed or refractory CD19+ a…

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This study tests a personalized vaccine made from a patient's own leukemia cells and immune cells. The goal is to see if the vaccine can help prevent the cancer from coming back after chemotherapy. It is for adults aged 55 and older with acute myeloid leukemia (AML) who are in re…

This phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatr…

This phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus a chemotherapy drug (azacitidine) in 99 people with myelodysplastic syndromes (MDS), a type of blood cancer. The goal is to see if the combination improves response rates, especially…

This study tests a new treatment for children and young adults up to age 30 whose leukemia or lymphoma has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are genetically modified in a lab to recognize and attack ca…

Standard treatment cures most children with aggressive mature B-cell lymphomas, but those whose cancer returns or resists therapy have few options. This phase 1b trial tests epcoritamab, an experimental immunotherapy given as an injection under the skin, in children and young adu…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…

This study tests whether asciminib is easier to tolerate than nilotinib in adults newly diagnosed with a type of leukemia called Philadelphia chromosome-positive CML. About 568 participants take either asciminib once daily or nilotinib twice daily. The main goal is to see how lon…

This early-phase trial tests a new drug called tegavivint, given together with the chemotherapy decitabine, for people whose leukemia has returned or not responded to standard treatments. The main goals are to find the safest dose and to watch for side effects. Only 9 adults with…

This study tests a combination of two drugs, vemurafenib (a pill) and obinutuzumab (an infusion), in 30 people with previously untreated hairy cell leukemia. The goal is to see how many patients achieve a complete response, meaning no signs of cancer after treatment. Participants…

This phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This study tests a new drug, ibrutinib, added to standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can clear all signs of leukemia from the bone marrow (called MRD-negative complete response)…

This Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also che…

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study looks at whether giving children with hard-to-cure leukemia a transfusion of white blood cells (granulocytes) after a cord blood transplant helps their new immune system grow faster and safer. About 40 children under 16 will receive this extra transfusion, and research…

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This study tests whether adding the drug venetoclax to standard chemotherapy can help treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and adults (18+) whose leukemia has come back or not responded to treatment. The goal is to find…

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…

This early-phase trial tests a new drug called ACY-1215 (ricolinostat) combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia has returned after prior treatment. The main goal is to find a safe dose, while also checking if the combination helps …

This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…

This early-phase trial is testing a drug called AZD6738 in 52 people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard therapy. The drug works by blocking a DNA repair pathway that cancer cells rely on, causing th…

This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.

This study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…

This phase II study tests a combination of two drugs, venetoclax and rituximab, in 25 people with chronic lymphocytic leukemia (CLL) that has relapsed or not responded to treatment. The goal is to see how well the combination works and how safe it is. Participants receive venetoc…

This early-phase study tests a new treatment called FT819 for people with B-cell cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The goal is to find a safe dose and see if the therapy can shrink tumors. About 54 participants will receive FT819 alo…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …

This study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …

This early-phase study tests whether the drug talazoparib can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a specific genetic mutation (cohesin) and cannot receive standard intensive chemotherapy. The main goal is to see if the drug red…

This Phase 1 trial aimed to test whether bone marrow from deceased, mismatched unrelated donors could be safely used for transplants in patients with blood cancers like leukemia. The approach used stored (cryopreserved) marrow along with drugs to prevent rejection. However, the s…

This study tests two experimental drugs (AG-120 and AG-221) that target specific genetic mutations (IDH1 or IDH2) found in some acute myeloid leukemia (AML) patients. Each drug is combined with a standard chemotherapy (azacitidine) and compared to azacitidine alone. The trial enr…

This study tests a new conditioning regimen using a precise type of radiation (helical tomotherapy) along with two chemotherapy drugs (fludarabine and melphalan) before a donor stem cell transplant. The goal is to reduce side effects and improve outcomes for people with leukemia …

This early-phase trial is testing whether a new immune cell therapy called CART123, given together with the drug ruxolitinib, is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The study will enroll 12 adults who have no other c…

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control th…

This early-phase study tests a new type of immunotherapy for children and young adults with leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize two different targets (CD19 and CD22) on leukemia cells, t…

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…

This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on canc…

This early-phase trial tests whether adding pulses of the cancer drug dasatinib to standard CAR T-cell therapy (brexucabtagene autoleucel) is feasible and safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants receive dasatinib on a we…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This early-phase trial tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) after a mini stem cell transplant in people aged 60 and older with certain blood cancers. The study also aims to see if itacitinib allows doctors to use…

This program provides revumenib (SNDX-5613) to patients with relapsed or refractory acute leukemias who cannot join other studies and have no approved treatments. Participants take the drug orally every 12 hours. The goal is to offer a potential treatment option in a controlled s…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This study tests whether a probiotic called Lactobacillus plantarum can prevent a serious complication called graft-versus-host disease (GvHD) in the gut of children receiving a donor stem cell transplant. About 173 children with blood cancers or other conditions are taking the p…

Researchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…

This study looks at whether a daily mindfulness app called Headspace can help adults who survived childhood cancer cope with stress. Fifty survivors will use the app for 30 days and wear a wrist device to track stress signs. The main goal is to see if people find the app acceptab…

This study is developing and testing a stepped-care program to help children with leukemia manage emotional and behavioral challenges like anxiety, sadness, and sleep problems. The program starts with simple support and adds more help as needed, including therapy sessions and par…

This study looks at whether starting palliative care early can help adults with aggressive leukemias or myelodysplastic syndrome (MDS) have a better end-of-life experience. Researchers will compare where patients die (home, hospice, or hospital) and how often they need hospital c…

This study tests whether adding methadone to usual morphine-based pain medicine reduces severe mouth pain in children aged 6–18 who are getting a stem cell transplant for leukemia, aplastic anemia, or similar conditions. The mouth pain is a common side effect of the chemotherapy …

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

Researchers at Peking University First Hospital are studying how the immune system responds to SARS-CoV-2 infection in people who have blood cancers compared with people who have no underlying diseases. The observational study enrolls 60 participants and collects clinical details…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study looks at how well children and teenagers who finished treatment for leukemia or non-Hodgkin lymphoma can perform everyday tasks like dressing, playing, and moving around. Participants will complete a questionnaire, an obstacle course, and a motor skills test to assess …

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study is testing whether a specially designed video game can help young people (ages 15-39) who have had a stem cell transplant for leukemia or lymphoma improve their health habits. Researchers will gather feedback from 40 participants to see if the game is easy and enjoyabl…

This study tests whether a short simulation training session helps nursing students learn how to manage a complication (extravasation) in an adolescent leukemia patient. 18 third-year nursing students will take part in a 46-minute session that includes a scenario and group discus…

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study follows 69 people infected with HTLV-1, some of whom have developed a rare blood cancer called adult T-cell leukemia/lymphoma. Researchers will track survival rates over 2 and 5 years, along with viral levels and genetic markers. The goal is to better understand how th…

This study was designed to learn more about different types of Candida fungus that cause serious bloodstream infections, and how they become resistant to medicines. The researchers planned to study samples from adult patients to track which species were most common and how they r…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This study collects blood and tissue samples from people receiving or donating bone marrow transplants for leukemia, lymphoma, or other blood diseases. Researchers will analyze these samples to find genes and proteins linked to cancer development and transplant complications. The…

This study is a large registry that collects information from children diagnosed with cancer across the US and Canada. Its goal is to help researchers understand patterns, causes, and characteristics of childhood cancer. No treatments or drugs are given—it is purely for research …

This pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …